Dr. Svenstrup will head up the company's oral osteoporosis program. Niels has over 25 years of experience in the pharmaceutical industry, including roles at BayerSchering Pharma, Bayer HealthCare, Cydan, and H.Lundbeck.

Dr. Svenstrup brings more than 20 years of experience in pharmaceutical research & development to OssiFi, where he will oversee the R&D process of the company’s osteoperosis platform. His work has resulted in the invention of numerous drug candidates, of which several are currently in clinical development. Prior to joining OssiFi he served in a variety of life science leadership roles, most recently as Senior Vice President of Development at PepGen, where he managed chemistry, manufacturing and controls (CMC) operations and strategy and led efforts to identify and de-risk therapeutic candidates. He previously served as Director of Project Management and CMC at Ascendis Pharma, where he supervised both CMC operations and preclinical development of first-in-class products for rare endocrinology diseases. He also held positions at H. Lundbeck as Head of Department, Medicinal Chemistry and Bayer as Strategic Project Leader, Oncology and Virology. Prior to his move to Bayer Pharmaceuticals, Dr. Svenstrup conducted postdoctoral research at The Scripps Research Institute in La Jolla, California. He holds a Ph.D. in Organic Chemistry and a M.Sc. in Cell Biology and Chemistry.

Return to Our Team here.